Ritonavir-boosted protease inhibitor based therapy: a new strategy in chronic hepatitis C therapy.
about
Hepatitis C treatment: where are we now?Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy.Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.Evaluation of a Potential Interaction Between New Regimens to Treat Hepatitis C and Warfarin.Inhibition of Human CYP3A4 by Rationally Designed Ritonavir-Like Compounds: Impact and Interplay of the Side Group Functionalities.
P2860
Ritonavir-boosted protease inhibitor based therapy: a new strategy in chronic hepatitis C therapy.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Ritonavir-boosted protease inh ...... n chronic hepatitis C therapy.
@en
type
label
Ritonavir-boosted protease inh ...... n chronic hepatitis C therapy.
@en
prefLabel
Ritonavir-boosted protease inh ...... n chronic hepatitis C therapy.
@en
P2860
P1476
Ritonavir-boosted protease inh ...... n chronic hepatitis C therapy.
@en
P2093
Samuel W Brayer
P2860
P304
P356
10.1586/17474124.2015.1032938
P577
2015-04-06T00:00:00Z